Organogenesis Holdings Inc. provided earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expects net revenue of between $465 million and $490 million, representing a decrease of approximately 1% to an increase of 5% year-over-year, and 2% to 7% on an adjusted basis, as compared to net revenue of $467.4 million for the year ended December 31, 2021. Net income in a range of approximately $26 million to $36 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.655 USD | -1.30% | -3.10% | -35.09% |
13/05 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
10/05 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.09% | 357M | |
+66.91% | 62.86B | |
-1.21% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.59% | 26.46B | |
-21.94% | 18.9B | |
+4.03% | 12.67B | |
+24.03% | 12.27B | |
+28.71% | 12.07B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022